News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

4-Antibody AG Meets First Milestone in Boehringer Ingelheim Corporation Collaboration


4/19/2011 9:43:47 AM

Basel, Switzerland, April 19th, 2011: 4-Antibody AG today announced that the Company has achieved the successful completion of a first milestone in its ongoing collaboration with Boehringer Ingelheim.

4-Antibody’s first R&D collaboration with a major pharma partner, Boehringer Ingelheim, commenced in early 2010 and is a long-term collaboration to discover and to develop fully human therapeutic antibodies for a number of targets in various disease indications. The collaboration centres on 4-Antibody’s proprietary high throughput in vitro Retrocyte Display® technology for rapid antibody discovery and also incorporates the novel, rapid, in vivo Hu-PAC® technology for the discovery and development of fully human antibodies against novel targets nominated by Boehringer Ingelheim.

Robert Burns, 4-Antibody’s CEO, said:

“Long-term collaborations serve an important role in validating technology platforms and so we’re delighted to announce that we’ve successfully delivered on the first major milestone in this key multi-target collaboration. I’d expect this to add further momentum to our other ongoing partnering activities.”

About 4-Antibody AG

4-Antibody is a biopharmaceutical company with a powerful fully-human antibody drug-discovery technology platform which is generating an emerging pipeline of antibody therapeutics. The proprietary discovery engine is the in-vitro Retrocyte Display® technology, a fast and highly efficient source of antibody drug candidates. Retrocyte Display® generates high quality therapeutic antibody drug candidates quickly using a rapid, high-throughput, flow cytometry approach incorporating full-length IgG format human antibody libraries expressed in mammalian B cells (the cell designed by nature for optimal antibody display). This in vitro process is supported by the in vivo HU-PAC® filter used to select only those antibody product candidates with the most desirable drug characteristics. 4-Antibody provides access to its technologies to select pharmaceutical R&D collaborators and is also generating an in-house pipeline of antibody drugs. The Company’s lead development product is an anti-cytomegalovirus antibody drug. 4-Antibody is a private company with strong, commercially-experienced leadership located in Basel, Switzerland and Jena, Germany. For more information please visit: www.4-antibody.com

Further Information:

Dr Robert Burns

CEO

4-Antibody AG

t: +41 61 697 1351

e: robert.burns@4-antibody.com

Dr Douglas Pretsell

Associate Partner

College Hill

t: +44 20 7866 7868

e: douglas.pretsell@collegehill.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES